APA (7th ed.) Citation

S, L., NA, K., A, S., DM, S., CJ, R., RC, S., . . . T, A. (2022). Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature communications, 13(1), 1379. https://doi.org/10.1038/s41467-022-28517-z

Chicago Style (17th ed.) Citation

S, Lin, et al. "Antibody Decay, T Cell Immunity and Breakthrough Infections Following Two SARS-CoV-2 Vaccine Doses in Inflammatory Bowel Disease Patients Treated with Infliximab and Vedolizumab." Nature Communications 13, no. 1 (2022): 1379. https://doi.org/10.1038/s41467-022-28517-z.

MLA (9th ed.) Citation

S, Lin, et al. "Antibody Decay, T Cell Immunity and Breakthrough Infections Following Two SARS-CoV-2 Vaccine Doses in Inflammatory Bowel Disease Patients Treated with Infliximab and Vedolizumab." Nature Communications, vol. 13, no. 1, 2022, p. 1379, https://doi.org/10.1038/s41467-022-28517-z.